Journal
MYC and BCL2 evaluation in routine diagnostics of aggressive B-cell lymphomas - presentation of a work-flow and the experience with 248 cases.
Since its initial description, the role of MYC (c-MYC) as a driving proto-oncogene in lymphomas has been a subject of significant focus (Ladanyi et al, 1991). In diffuse large B-cell lymphomas (DLBCL), MYC translocation, as well as additional translocations of BCL2 are known to be associated with an adverse outcome (Savage et al, 2009). Furthermore, Hu et al (2013) showed that concerted expression of MYC (c-MYC) and BCL2 is an independent predictor of poor prognosis regardless of rearrangement of the MYC locus.